Media-no-image

​Data at EULAR 2015 Showcase Commitment of Janssen to Advancing Innovative Treatments for Immune and Inflammatory Diseases

Pressemeddelelser   •   2015-06-11 08:00 CEST

New data highlights efficacy and safety of STELARA® (ustekinumab), sirukumaband guselkumab.

The Janssen Pharmaceutical Companies* presented 11 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, at the Annual European Congress of Rheumatology (EULAR), 10–13 June, in Rome, Italy.

Newman Yeilding, M.D., Head of Immunology Development, Janssen Research & Development, LLC. said,“Our commitment to immunology and the continued research and development of innovative solutions for the treatment of complex immune and inflammatory diseases has never been stronger. We are pleased to present data from our immunology portfolio at the EULAR congress.”

Janssen Immunology Portfolio Highlights At EULAR 2015 Include:1

STELARA (ustekinumab):

  • Serum biomarkers associated with disease activity and response to ustekinumab in patients with ankylosing spondylitis in the TOPAS study (THU0194)
    - Poster presentation, Thursday 11 June at 12:00
    - Lead author: B. Dasgupta
  • Efficacy and safety of ustekinumab in psoriatic arthritis patients with spondylitis and peripheral joint involvement: Results from a Phase 3, multicenter, double-blind, placebo-controlled study† (OP0174)
    - Oral presentation, Friday 12 June at 11:35
    - Lead author: A. Kavanaugh

Sirukumab:

  • Neutralization of IL-6 by sirukumab inhibits inflammation and cellular stress in a human vascular surrogate system of atherosclerosis (FRI0069)
    - Poster and poster tour presentation, Friday 12 June at 13:25
    - Lead author: B. Hsu

Contact information:

Media Contacts:
Matti Ojanen
Office: +34 91 722 8079
Mobile: +34 678 404 870

Brian Kenney
Office: +1 215-628-7010
Mobile: +1 215-620-0111

Investor Contacts:
Louise Mehrotra
Johnson & Johnson
Office + 1 732 524 6491

Lesley Fishman
Johnson&Johnson
Office: +1732 524 39 22

About Ankylosing Spondylitis

Ankylosing spondylitis is a chronic, immune-mediated disease that causes enthesitis, or inflammation where ligaments and muscles attach to bones, most commonly those within the spine. It is the primary disease in a group of arthritis-related diseases known as spondylitis, spondyloarthropathy or spondyloarthritis.2,3 It is estimated that 0.1 to 1.4 percent of the world’s population are living with ankylosing spondylitis.4 The disease affects men more often than women and typically manifests in early adulthood.5 In contrast to mechanical low back pain, low back pain and stiffness with ankylosing spondylitis worsen after a period of rest or upon waking up in the morning and improve after exercise, a hot bath or a shower.2

About Rheumatoid Arthritis

Rheumatoid arthritis is a chronic inflammatory disorder that occurs when the immune system attacks the lining of the membranes that surround joints, also known as the synovium. Unlike the wear-and-tear damage associated with other types of arthritis, rheumatoid arthritis causes painful swelling and destroys the cartilage and bone, eventually resulting in permanent joint deformity. Rheumatoid arthritis can be difficult to diagnose in its initial stages because the early signs and symptoms mimic those of many other diseases. Currently, there is no single blood test or physical finding to confirm the diagnosis.6 It is estimated that 0.3 to 1 percent of the world’s population are living with rheumatoid arthritis. The disease is most common in women and is more prevalent in developed countries. It tends to strike during the most productive years of adulthood, between the ages of 20 and 40.7

About Psoriatic Arthritis

Psoriatic arthritis is a chronic immune-mediated inflammatory disease characterised by both joint and surrounding tissue inflammation, and the skin lesions associated with psoriasis, which affects as many as 37 million people worldwide8 and approximately 4.2 million people across Europe.8,9,10,11,12,13 While estimates of the prevalence of psoriatic arthritis among people living with psoriasis vary, up to 30 percent may develop inflammatory arthritis. 13 Although the exact cause of psoriasis arthritis is unknown, it is believed to be an immune-mediated inflammatory disease with genetic link. 14 Environmental factors may play a role in the development of the disease.15 Early signs of psoriatic arthritis can include enthesitis and dactylitis. Other arthritic symptoms of psoriatic arthritis include swelling, pain, stiffness of the joints and surrounding tissue, and reduced range of motion.14,16

About Psoriasis

Psoriasis, a chronic, immune-mediated disease that results from the overproduction of skin cells, affects 125 million people worldwide, including nearly 14 million Europeans.9-13 Plaque psoriasis often results in patches of thick, red or inflamed skin covered with silvery scales known as plaques. These plaques can crack and bleed, and may occur anywhere on the body.17 The disease symptoms can range from mild, to moderate, to severe and disabling. It is estimated that nearly three percent of the world’s population is living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.12

About STELARA (ustekinumab)18

STELARA, a human interleukin (IL)-12 and IL-23 antagonist, is approved for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or psoralen plus Ultraviolet A (PUVA). STELARA is also approved alone or in combination with MTX, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.

STELARA is not recommended for use in children and adolescents below the age of 18.

The Janssen Pharmaceutical Companies maintain exclusive worldwide marketing rights to STELARA, which is currently approved for the treatment of moderate to severe plaque psoriasis in 84 countries and for psoriatic arthritis in 55 countries.

Important Safety Information18

SPECIAL WARNINGS & PRECAUTIONS: Infections: Potential to increase risk of infections and reactivate latent infections. Exercise caution in patients with a chronic infection or history of recurrent infection, particularly TB. Patients should be evaluated for tuberculosis and treated for latent TB prior to initiation of STELARA. Also, consider anti-tuberculosis therapy prior to initiation of STELARA in patients with past history of latent or active tuberculosis. Patients should seek medical advice if signs or symptoms suggestive of an infection occur. If a serious infection develops, they should be closely monitored and STELARA should not be administered until infection resolves. Malignancies: Potential to increase the risk of malignancy. No studies have been conducted in patients with a history of malignancy or in those who continue to receive STELARA after being diagnosed with a malignancy. Exercise caution when considering STELARA in these patients. Monitoring for the appearance of non-melanoma skin cancer recommended, in particular for patients greater than 60 years of age, or with a medical history of prolonged immunosuppressant therapy or a history of PUVA treatment. Hypersensitivity reactions: Serious hypersensitivity reactions (anaphylaxis and angioedema) reported, in some cases several days after treatment. If these occur, institute appropriate therapy and discontinue use of STELARA. Vaccinations: Patients receiving STELARA should not receive concurrent live viral or live bacterial vaccines such as BCG. Before live viral or live bacterial vaccination, treatment with STELARA should be withheld for at least 15 weeks after the last dose and can be resumed at least 2 weeks after vaccination. Patients receiving STELARA may receive concurrent inactivated or non live vaccinations. Concomitant immunosuppressive therapy: Exercise caution, including when changing immunosuppressive biologic agents. In psoriasis studies,the safety and efficacy of STELARA in combination with other immunosuppressants, including biologics, or phototherapy have not been evaluated. In psoriatic arthritis studies, concomitant MTX use did not appear to influence the safety or efficacy of STELARA. Immunotherapy: Not known whether STELARA affects allergy immunotherapy. Serious skin conditions: In patients with psoriasis, exfoliative dermatitis has been reported following STELARA treatment. Patients with plaque psoriasis may develop erythrodermic psoriasis, with symptoms that may be clinically indistinguishable from exfoliative dermatitis, as part of the natural course of their disease. If these symptoms occur, appropriate therapy should be instituted. STELARA should be discontinued if a drug reaction is suspected. Latex sensitivity: Needle cover contains natural rubber (latex), may cause allergic reactions. Elderly Patients > 65years: Use caution when treating elderly patients.

For complete European Union (EU) prescribing information, please visit: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000958/human_med_001065.jsp&mid=WC0b01ac058001d124

About Sirukumab

Sirukumab is an investigational human monoclonal IgG1 kappa antibody in Phase 3 development for the treatment of moderately to severely active rheumatoid arthritis.19 It is not approved as a treatment for rheumatoid arthritis or any other indication anywhere in the world. Sirukumab targets the cytokine interleukin IL-6, a naturally occurring protein that is believed to play a role in autoimmune conditions like rheumatoid arthritis.20

Janssen Research & Development, LLC was developing sirukumab for rheumatoid arthritis and in December 2011, Janssen Biologics (Ireland) and GSK entered into a co-development and co-commercialisation license agreement with respect to sirukumab to continue such development.

About Guselkumab21

Guselkumab is an investigational human monoclonal antibody that targets interleukin IL-23 and is currently in Phase 3 study for the treatment of moderate to severe plaque psoriasis. It is not approved as a treatment for plaque psoriasis or any other indication anywhere in the world. Guselkumab is being studied to determine whether blockade of IL-23 alone can achieve high levels of complete skin clearance.

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in immunology, oncology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people with serious diseases throughout the world. Beyond its innovative medicines, Janssen is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and health care professionals have access to the latest treatment information, support services and quality care.

*The Janssen Pharmaceutical Companies operate through different legal entities in various countries. Therefore, the legal entity acting as the sponsor or the marketing authorisation holder may vary. Janssen Research & Development, LLC, Janssen Biotech, Inc.; Janssen Biologics, BV; Janssen-Cilag International NV are all Janssen affiliates. Please visit www.janssen-emea.com for more information. Follow us on www.twitter.com/JanssenEMEA.

# # #

References

1. EULAR congress. Available at http://www.congress.eular.org (last accessed May 2015).
2. Spondylitis Assoication of America. About ankylosing spondylitis. Available at http://www.spondylitis.org/about/as.aspx (last accessed May 2015).
3. Arthritis Foundation. Ankylosing Spondylitis. Available at http://www.arthritis.org/about-arthritis/types/ankylosing-spondylitis (last accessed May 2015).
4. Dean LE, et al. Global prevalence of ankylosing spondylitis. Rheumatology 2014;53:650–657.
5. Mayo Clinic. Ankylosing Spondylitis. Available at http://www.mayoclinic.org/diseases-conditions/ankylosing-spondylitis/basics/definition/con-20019766?p=1(last accessed May 2015).
6. Mayo Clinic. Rheumatoid arthritis. Available at http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/basics/symptoms/con-20014868?p=1 (last accessed May 2015).
7. World Health Organization. Chronic rheumatic conditions. Available at http://www.who.int/chp/topics/rheumatic/en(last accessed May 2015).
8. National Psoriasis Foundation. Psoriatic arthritis: about psoriatic arthritis. Available at http://www.psoriasis.org/psoriatic-arthritis(last accessed May 2015).
9. Augustin M, et al. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers Br J Dermatol 2011;165:865–873.
10. Parisi R, et al. Global Epidemiology of Psoriasis: A Systematic Review. J Invest Dermatol 2013;133:377–385.
11. Ortonne J, et al. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur J Dermatol 2004;14:41–45.
12. National Psoriasis Foundation. What is known about psoriasis: statistics. Available at https://www.psoriasis.org/cure_known_statistics(last accessed May 2015).
13. National Psoriasis Foundation. Psoriatic arthritis: about psoriatic arthritis. Available at http://www.psoriasis.org/psoriatic-arthritis(last accessed May 2015).
14. FitzGerald O, et al. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009;11:214.
15. Chandran V, et al. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis – Abstract. J Autoimmun 2010;34:J314–321.
16. Amherd-Hoekstra A, et al. Psoriatic arthritis: a review. J Dtsch Dermatol Ges 2010;8:332–339.
17. European Union website. How many people live in the EU? Available at https://psoriasis.org/about-psoriasis(last accessed May 2015).
18. Summary of Product Characteristics Stelara 45 mg solution. Janssen-Cilag International NV. Last updated September 2013. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf(last accessed May 2015).
19. Smolen et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014;73:1616-1625.
20. Rossi et al. Interleukin-6 as a Therapeutic Target. Clin Can Res 2015;21(6):1248-1257.
21. Mansouri Y, Goldenberg G. New systemic therapies for psoriasis. Cutis 2015;95:155-160.

Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

New data highlights efficacy and safety of STELARA® (ustekinumab), sirukumaband guselkumab. The Janssen Pharmaceutical Companies* presented 11 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, at the Annual European Congress of Rheumatology (EULAR), 10–13 June, in Rome, Italy.

Læs mere »
Media-no-image

Endnu et fase III-studie overbeviser om effekt af ny leukæmi-behandling

Pressemeddelelser   •   2015-06-01 16:50 CEST

Behandling med lægemidlet ibrutinib (IMBRUVICA®) i kombination med standardbehandlingen bendamustin og rituximab har i nyt fase III-studie vist at kunne reducere progressionsrisikoen for CLL (kronisk lymfatisk leukæmi) med 80 %.

I et nyt studie, kaldet HELIOS, har behandling med ibrutinib i kombination med standardbehandlingen bendamustin og rituximab hos CLL-patienter og SLL-patienter (småcellet Lymfocytisk Lymfom) vist at reducere risikoen for progression med 80 % og øge den progressionsfrie overlevelse signifikant. Resultaterne offentliggøres i dag på den internationale kræftkongres ASCO (American Society of Clinical Oncology) i Chicago.

”Helios studiet er bemærkelsesværdigt, specielt fordi gevinsten ved behandlingen med ibrutinib, bendamustin og rituximab opnås uafhængigt af hvilken risikoprofil CLL-patienten har. Dog er patienter med den dårligste prognose (CLL-patienter med 17p-deletion) ekskluderet,” udtaler overlæge Ilse Christiansen, Aalborg Universitetshospital, som er formand for CLL-udvalget i Dansk Lymfom Gruppe.

Patienter skiftet fra placebo til ibrutinib
Studiet, der er randomiseret og dobbeltblindet, er gennemført med 578 CLL-patienter fra 21 lande. Alle patienter har tidligere modtaget anden behandling. Omkring halvdelen af patienterne har modtaget ibrutinib (420 mg tabletbehandling en gang dagligt) i kombination med bendamustin og rituximab (6 behandlingscykler) og den anden halvdel har modtaget tilsvarende mængde placebo-tabletbehandling i kombination med samme antal bendamustin- og rituximab-behandlingscykler.

Dette er det andet fase III-studie, der er gennemført med ibrutinib, og resultaterne har vist sig så gode, at studiet blev stoppet efter anbefaling fra en uafhængig datamonitoreringskomité (IRC) ved første planlagte interim analyse tidligere i år.

Ved 18 måneder var den progressionsfri overlevelse (PFS) for ibrutinib, bendamustin og rituximab armen på 79 %, sammenlignet med 24 % for placebo, bendamustin og rituximab. Den mediane progressionsfri overlevelse var 13,3 måneder for patienter behandlet med placebo, bendamustin og rituximab, men ikke nået i den eksperimentale arm. Dette førte til, at 31 % af patienterne i placebo-gruppen blev skiftet over til at modtage ibrutinib.

”Ved en interim-analyse blev data åbnet, og på baggrund af den højsignifikante forskel fik ca. 90 patienter i placeboarmen tillæg af Ibrutinib,” udtaler Ilse Christiansen.

Mild tablet-behandling
Bivirkningsprofilen for ibrutinib er relativ mild. De mest almindelige bivirkninger hos forsøgspatienterne var neutropeni (lavt antal hvide blodlegemer), kvalme og trombocytopeni (lavt antal blodplader). Hos de patienter, der fik ibrutinib + bendamustin og rituximab, sås neutropeni hos 58,2 % mod 54,7 % hos de patienter, der fik placebo + bendamustin og rituximab. Kvalme sås hos 36,9 % vs. 35,2 % og trombocytopeni hos 15 % i begge grupper.

Kontakt 
For yderligere information kontakt venligst:
Overlæge Ilse Christiansen, e-mail: ilse.christiansen@rn.dk, telefon: +45 97 66 38 54.
Public Affairs Leader Inger Sandberg, e-mail: isandber@its.jnj.com, telefon: +45 29 99 82 56.

Fakta om kronisk lymfatisk leukæmi
I Danmark lever omkring 2.500 mænd og kvinder med diagnosen CLL (kronisk lymfatisk leukæmi). 5-års overlevelsen hos mænd er 79 % og 90 % hos kvinder. CLL er generelt en langsomt voksende form for leukæmi, der opstår i en særlig type af de hvide blodlegemer kaldet B-celler. B-cellerne er en del af immunsystemet og spiller en vigtig rolle for kroppens forsvar mod infektioner. CLL er resultatet af en funktionsfejl i B-cellerne, som gør dem ondartede og får dem til at vokse og dele sig hurtigt og uhæmmet.

Uddybende fakta om CLL er vedhæftet.

Fakta om Imbruvica
IMBRUVICA® (ibrutinib) er en såkaldt proteinkinasehæmmer, der virker ved at blokere overførslen af celleoverlevelsessignaler i kræftcellerne. IMBRUVICA® er godkendt til behandling af CLL og MCL (mantle celle lymfom) i Europa, og der forskes derudover i effekten af midlet inden for andre typer af lymfe- og blodkræft, samt i virkningen ved kombination med andre behandlinger.

IMBRUVICA® er udviklet i et samarbejde mellem Cilag GmbH International og Pharmacyclics Inc. og markedsføres i Danmark af Janssen. Lægemidlet er i Danmark godkendt til behandling af voksne patienter med recidiverende eller refraktært mantle celle lymfom (MCL) samt behandling af voksne patienter med kronisk lymfatisk leukæmi (CLL), som har modtaget mindst én tidligere behandling, eller som første linje behandling ved tilstedeværelse af 17p-deletion eller TP53-mutation hos patienter, for hvem kemo-immunterapi ikke er egnet.

Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

Behandling med lægemidlet ibrutinib (IMBRUVICA®) i kombination med standardbehandlingen bendamustin og rituximab har i nyt fase III-studie vist at kunne reducere progressionsrisikoen for CLL (kronisk lymfatisk leukæmi) med 80 %.

Læs mere »
Media-no-image

Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia

Pressemeddelelser   •   2015-05-27 10:00 CEST

A rare B-cell lymphoma with no EMA-approved treatment options available

Beerse/Belgium, Friday, 22 May 2015 – Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a change to the terms of the marketing authorisation for IMBRUVICA® (ibrutinib) in the European Union, to indicate the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.1 IMBRUVICA is co-developed by Cilag GmbH International (a member of the Janssen Pharmaceutical Companies) and Pharmacyclics, Inc. Janssen affiliates market IMBRUVICA in EMEA (Europe, Middle East and Africa) as well as the rest of the world, except for the United States, where Janssen Biotech, Inc. and Pharmacyclics. co-market it.

IMBRUVICA is already approved in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.2 If approved by the European Commission, IMBRUVICA would become the first approved treatment for WM across the EU. It has also recently been approved in WM by the U.S. FDA.

“Janssen welcomes this positive opinion recommending the approval of an additional indication for IMBRUVICA,” said Jane Griffiths, Company Group Chairman, Janssen EMEA. “Waldenström’s macroglobulinemia is a serious blood cancer with no EMA-approved treatment options currently available. We are pleased to be one step closer to offering patients a targeted treatment for this rare disease.”

WM is a slow-growing and rare type of blood cancer.3,4 WM originates from B cells, a type of white blood cell (lymphocyte), and develops in the bone marrow.3,4 The median age at diagnosis is 63-68 years5,6 and incidence rates among men and women in Europe are approximately 7.3 and 4.2 per million persons, respectively.6

Genome sequencing of patients with WM has revealed a common mutation in the MYD88 gene. This mutation triggers the activation of the enzyme Bruton’s tyrosine kinase (BTK), which is a key component needed to regulate immune cell proliferation and cell survival which plays a part in B-cell malignancies, such as WM.7 IMBRUVICA forms a strong covalent bond with BTK, thereby inhibiting the enzyme and blocking the transmission of cell survival signals within the malignant B cells.8

The Phase 2 multi-centre study on which the CHMP recommendation was based evaluated the efficacy and tolerability of IMBRUVICA 420 mg once daily in 63 patients with previously treated WM (median age of 63; range, 44-86 years old). Updated results from the study were published on 8 April, 2015 in an online edition of The New England Journal of Medicine.9 The overall response rate using criteria adopted from the International Workshop on WM was 90.5 percent, 57 out of 63 patients. Eleven patients (17 percent) achieved a minor response, 36 patients (57 percent) achieved a partial response (PR) and 10 patients (16 percent) achieved a very good PR. The median times to at least minor and partial responses were four weeks and eight weeks, respectively.9

Secondary endpoints included progression free survival (PFS) and the safety and tolerability of IMBRUVICA in symptomatic patients with relapsing/remitting WM. The estimated two–year PFS and overall survival (OS) rates among all patients were 69.1 percent and 95.2 percent respectively.9

The most commonly occurring adverse reaction in the WM trial (14 patients, or 22 percent) was neutropenia (decreased amount of neutrophils in the blood). Thrombocytopenia (decrease in platelets in the blood) occurred in nine patients (14 percent), and other adverse events occurred in less than five patients (<10 percent) each. Four patients (six percent) in the WM trial receiving IMBRUVICA discontinued treatment due to neutropenia or thrombocytopenia. Additionally these two adverse events lead to dose reduction in three patients (five percent).9

Media Inquiries:
Natalie Buhl
Mobile: +353 (0)85 744 6696
Email: nbuhl@its.jnj.com

Investor Relations:
Lesley Fishman
Phone: +1 732-524-3922

Louise Mehrotra
Phone: +1 732-524-6491

About IMBRUVICA®

IMBRUVICA (ibrutinib) is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, which works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B cells.8 By blocking this BTK protein, IMBRUVICA helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.10

IMBRUVICA is approved in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line patients with CLL in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy;2 regulatory approval for additional uses has not yet been granted. Investigational uses for ibrutinib, alone and in combination with other treatments, are under way in several blood cancers including CLL, MCL, Waldenström's macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM) and marginal zone lymphoma (MZL).

IMBRUVICA is co-developed by Cilag GmbH International (a member of the Janssen Pharmaceutical Companies) and Pharmacyclics, Inc. Janssen affiliates market IMBRUVICA in EMEA (Europe, Middle East and Africa) as well as the rest of the world, except for the United States, where Janssen Biotech, Inc. and Pharmacyclics. co-market it. Janssen and Pharmacyclics are continuing an extensive clinical development programme for IMBRUVICA, including Phase 3 study commitments in multiple patient populations.

About Waldenströms Macroglobulinemia

Waldenström’s macroglobulinemia (WM) is a slow-growing, incurable, rare type of B-cell lymphoma for which no established standard of care, or EMA-approved therapeutic, exists.3,4 WM begins with a malignant change to the B cell, a type of white blood cell (lymphocyte), during its maturation so that it continues to reproduce more malignant B cells. WM cells make large amounts of a certain type of antibody (immunoglobulin M, or IgM). Antibodies such as IgM normally help the body to fight infection. Excess IgM causes the blood to thicken and causes many of the symptoms of WM, including among others excess bleeding and problems with vision and the nervous system.3,4

Janssen in Oncology

In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include a focus on haematologic malignancies, prostate cancer and lung cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment.

About Janssen

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the recommendation by the CHMP for the approval of a new indication. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; manufacturing difficulties and delays; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnsons Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the companys subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.)

References

1.European Medicines Agency. Committee for Medicinal Products for Human Use: Summary of opinion. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003791/WC500187054.pdf. Last accessed May 2015

2.European Medicines Agency. Committee for Medicinal Products for Human Use: Summary of opinion. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003791/WC500170191.pdf. Last accessed March 2015.

3.American Cancer Society. Detailed guide: Waldenstrom macroglobulinemia. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf Last accessed March 2015.

4.Leukemia and Lymphoma Society. Waldenström macroglobulinemia facts. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/waldenstrommacroglobulinemia.pdf. Last accessed March 2015.

5.Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol. 2007;138:700-20.

6.Buske C, Leblond V, Dimopoulos M, et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi155–vi159.

7.Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors. J Clin Oncol. 2012;30(Suppl.):abstract 8106.

8.O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.

9.Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430-40.

10.European Medicines Agency. How is the medicine expected to work? http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&amp;mid=WC0b01ac058001d12b. Last accessed March 2015. 

Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

A rare B-cell lymphoma with no EMA-approved treatment options available.

Læs mere »
Zwzcbwx32zv4ntyv6uuw

Janssen lancerer ny europæisk sygdomshjemmeside

Pressemeddelelser   •   2015-04-20 07:55 CEST

I disse dage lanceres Janssen EU Disease Lens – en vidensdatabase med information om 15 af de største sygdomme på tværs af de 28 EU medlemslande.

Media-no-image

Ny forenklet behandling til danskere som lever med HIV

Pressemeddelelser   •   2015-03-17 08:30 CET

De danske sundhedsmyndigheder har netop godkendt REZOLSTA®, en ny lægemiddelkombination, som gør livet nemmere for HIV-ramte danskere.

Nu er der godt nyt til danske HIV-patienter. I disse dage lancerer medicinalfirmaet Janssen HIV-lægemidlet REZOLSTA®, som består af darunavir (PREZISTA®) og boosteren cobicistat kombineret i samme tablet i stedet for to.

Lægemidlet blev i 2014 godkendt til markedsføring i EU og fås nu i Danmark1.

- Der er stor erfaring med darunavir i behandlingen af HIV4-9. Nu kan darunavir gives med booster i samme tablet, hvilket forenkler behandlingen for mange HIV-patienter, da de slipper for at tage to tabletter dagligt,” siger Stefan Lindbäck, Senior Medical Advisor hos Janssen.

Godkendelsen er baseret på bioækvivalensdata, som har vurderet den faste dosiskombination darunavir/cobicistat sammenlignet med darunavir boostet med ritonavir2, og desuden et fase 3-studie, som vurderede sikkerhed og effekt af darunavir/cobicistat til behandling af HIV-1-infektion hos voksne3.

REZOLSTA®(darunavir 800 mg/cobicistat 150 mg) er beregnet til anvendelse i kombination med andre antiretrovirale lægemidler til behandling af human immundefekt virus (HIV-1)-infektionhos voksne på 18 år eller derover1.

Yderligere information:
Inger Sandberg, Public Affairs Leader, isandber@its.jnj.com, + 45 29998256
Stefan Lindbäck, Senior Medical Advisor, slindback@its.jnj.com, +46 8 626 5054

# # #

Om HIV
Cirka 75 millioner er smittet med HIV siden epidemien startede10. Skønsmæssigt lever 35 millioner mennesker i verden med sygdommen i dag, og hvert år smittes yderligere ca. 2,5 millioner10,11.

Om PREZISTA® (darunavir)
Darunavir er en proteasehæmmer til behandling af human immundefekt virus (HIV-1)-infektion og tages altid sammen med ritonavir (til voksne og børn fra 3 år) eller cobicistat (kun voksne). Darunavir blev første gang godkendt i Europa i 2007 til meget behandlingserfarne HIV-1 patienter. Indikationen er siden udvidet til også at inkludere patienter, der er behandlingsnaive, behandlingserfarne og børn (på 3 år og derover, som vejer mindst 15 kg)12.

Om TybostTM (cobicistat)
TybostTM (cobicistat 150 mg) er en selektiv hæmmer af subfamilien CYP3A af cytokrom P450. Den booster koncentrationen af darunavir og atazanavir ved at hæmme CYP3A, et enzym som metaboliserer disse lægemidler i kroppen. Cobicistat har ingen egen antiviral aktivitet13,14. Cobicistat er udviklet af Gilead og anvendes ud over som booster til darunavir og atazanavir, også i STRIBILD (elvitegravir/cobicistat/emtricitabin/tenofovir). Gilead er ansvarlig for produktion, udvikling og markedsføring af cobicistat som enkeltprodukt.

Janssen og HIV
Janssen er engageret i forskning og udvikling af lægemidler til behandling af HIV-infektion og har i dag 4 lægemidler registreret til behandling af HIV-1-infektion (REZOLSTA®, PREZISTA®, INTELENCE® og EDURANT®). Janssen udfører også tidlig grundforskning i HIV-vaccine.

Referencer

1.REZOLSTA® Summary of Product Characteristics Nov 2014
2.Kakuda TN et al. J Clin Pharmacol. 2014; 54: 949–57
3.Tashima et al. AIDS Research and Therapy 2014 ; 11: 39
4.Llibre JM et al. AIDS Rev 2013; 15: 112-121
5.Ortiz R et al. AIDS 2008; 22: 1389-1397
6.Mills AM et al. AIDS 2009; 23: 1679-1688
7.Orkin C et al. HIV Med 2013; 14: 49-59
8.Cahn P et al. AIDS 2011; 25: 929-939.
9.Nelson M et al. J Antimicrob Chemother 2010; 65: 1505-1509
10.World Health Organization. Global Health Observatory (GHO). HIV/AIDS. Available at: http://www.who.int/gho/hiv/en/ Last accessed November 2014.
11.World Health Organization. Global summary of the AIDS epidemic 2011. Available at: http://www.who.int/hiv/data/2012_epi_core_en.png Last accessed November 2014
12.PREZISTA® Summary of Product Characteristics Nov 2014
13.Marknadsförs som Tybost™ av Gilead Sciences Sweden AB
14.TybostTM Summary of Product Characteristics Oct 2014

Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

De danske sundhedsmyndigheder har netop godkendt REZOLSTA®, en ny lægemiddelkombination, som gør livet nemmere for HIV-ramte danskere.

Læs mere »
Media-no-image

Banebrydende kræftlægemiddel klar til brug i Danmark

Pressemeddelelser   •   2014-12-16 16:59 CET

IMBRUVICA®, som er baseret på det aktive stof IBRUTINIB, er det første lægemiddel af en ny type kræftlægemidler, der fungerer ved at hæmme et særligt protein, ‘Brutons Tyrosin Kinase’ (BTK), som hjælper visse kræftceller med at overleve og formere sig. Dermed kan lægerne helt stoppe udviklingen af kræftceller, hvilket både øger levetiden for patienterne og minimerer de ellers svære bivirkninger, der er forbundet med fx kemoterapi. Med godkendelsen af IMBRUVICA® i Danmark er der banet vej for et paradigmeskifte i den danske lymfom- og leukæmibehandling.”Med de nye kinasehæmmere bevæger vi os væk fra den hårde kemoterapibehandling og mod en mere målrettet, intelligent behandling, helt nede på det molekylære niveau. Vi er så at sige helt inde i sygdommens maskinrum. Man kan endnu ikke tale om helbredelse, men vi har mulighed for at bringe sygdommen under kontrol. Og det vil forbedre både symptomer og overlevelse betydeligt hos patienterne,” fortæller Christian Geisler, professor på hæmatologisk afdeling på Rigshospitalet.”Foran os venter en årrække med store studier, der lære os at kombinere de nye lægemidler til CLL og de andre B-celle lymfekræftsygdomme. Det nye lægemiddel afspejler et paradigmeskift i behandlingen og er absolut godt nyt for patienterne, ” siger Christian Geisler.Overbevisende resultater – få bivirkningerPå grund af særdeles gode resultater fra hhv. fase 2 og 3 forsøg, blev IMBRUVICA® allerede i november 2013 godkendt i USA under en fremskyndet godkendelsesproces. Det er muligt ved behandlinger af livstruende sygdomme, når de kliniske data er så overbevisende, at det må anses for givet, at lægemidlet vil gavne patienterne. I oktober i år kom så den europæiske godkendelse, og fra i dag kan de danske patienter med de to sjældne blodkræftsygdomme så se frem til at blive behandlet med IMBRUVICA®.Hos patientforeningen for lymfekræft og leukæmi, LyLe, glæder de sig over den nye behandlingsmulighed og ser positivt på de få bivirkninger.”Som patientforening er vi først og fremmest optaget af patienternes livskvalitet og af at de får det bedre i hverdagen. Derfor er det meget glædeligt, at der her kommer en ny behandling, der har få bivirkninger og som efter alt at dømme har en livsforlængende effekt”, siger Rita O. Christensen, som er formand i LyLe. Fordi IMBRUVICA® tages som tabletter én gang dagligt, kan patienterne behandles hjemme

.IMBRUVICA® er udviklet i samarbejde mellem Cilag GmbH International og Pharmacyclics Inc. og markedsføres i Danmark af Janssen-Cilag A/S. Lægemidlet er i Danmark godkendt til:• Behandling af voksne patienter med recidiverende eller refraktært mantle celle lymfom (MCL)• Behandling af voksne patienter med kronisk lymfatisk leukæmi (CLL), som har modtaget mindst én tidligere behandling, eller som første linje behandling ved tilstedeværelse af 17p-deletion eller TP53-mutation hos patienter, for hvem kemo-immunterapi ikke er egnet.

FAKTABOKS om kronisk lymfatisk leukæmi (CLL):- CLL er generelt en langsomt voksende form for leukæmi, der opstår i en særlig type af de hvide blodlegemer kaldet B- lymfocytterne.- B-cellerne er en del af immunsystemet og spiller en vigtig rolle for kroppens forsvar mod infektioner. CLL er resultatet af en funktionsfejl i B-cellerne, som gør dem ondartede og får dem til at vokse og dele sig hurtigt og uhæmmet.- CLL ses oftere hos mænd end hos kvinder og gennemsnitsalderen på diagnosetidspunktet er 70 år.- Den gennemsnitlige overlevelse er ca. 10 år.- Nogle patienter med CLL oplever slet ingen symptomer og skal ikke behandles, men mulige tegn på CLL kan blandt andet være træthed og natlige svedeture, hævede lymfeknuder, smerte eller forstørret milt

.Om mantle celle lymfom (MCL):- MCL påvirker lymfesystemet og er en aggressiv form for lymfom, der ligeledes opstår i B- lymfocytterne.- MCL opstår ved en genetisk mutation i B-lymfocytterne i lymfeknudernes såkaldte mantle zone. På diagnosetidspunktet er halvdelen typisk udbredt til knoglemarven, leveren, milten og tarmsystemet.- MCL er mest udbredt blandt mænd.- Gennemsnitsalderen på diagnosetidspunktet er 70 år, mens den gennemsnitlige overlevelse er ca. 5 år.- De mest almindelige tegn på MCL er vedvarende træthed, uforklarligt vægttab, hævede lymfeknuder, forstørret lever og milt, diarré.

KILDER:1. IMBRUVICA® EPAR  2. IMBRUVICA® produktinformation pr. 25. november 2014

Ved spørgsmål kontakt venligst Public Affairs Leader Inger Sandberg, e-mail: isandber@its.jnj.com eller mobiltelefon: +45 29 99 82 56



Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, blodkræft, myelomatose, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

Janssen-Cilag A/S er klar med en ny, banebrydende kræftbehandling: Koordineringsrådet for Ibrugtagning af Sygehusmedicin (KRIS) har den 10. december godkendt IMBRUVICA® som standardbehandling af to typer blodkræft, som omfatter hhv. mantle celle lymfom (MCL) og kronisk lymfatisk leukæmi (CLL).

Læs mere »
Media-no-image

Janssen satser på hurtig produktion af Ebola-vaccine – De første doser tilgængelige allerede næste år

Pressemeddelelser   •   2014-10-27 10:30 CET

Janssens Ebola-vaccine har vist meget gode resultater i den prækliniske fase. Derfor bruger virksomheden nu omkring 1.200 millioner dansk kroner kroner på at fremskynde produktionen af vaccinen. Allerede i starten af januar 2015 bliver vaccinen testet på raske frivillige. I 2015 regner Janssen med at kunne producere over en million doser.

”Ebola er en alvorlig og stigende trussel mod befolkningen i Vestafrika, og den har potentiale til at sprede sig til mennesker i andre dele af verden. Vi vil bidrage med vores videnskab, teknik, innovation og ressourcer for at forebygge og behandle denne dødelige sygdom," siger adm. dir. Lars Johansson, Janssen i Norden.

Vaccinen blev opdaget ved et forskningsprogram, hvor Johnson & Johnson samarbejdede med National Institute of Health (NIH) og den danske biotekvirksomhed Bavarian Nordic. På baggrund af de lovende resultater blev det i september i år besluttet at tildele vaccinen et såkaldt fast-track. Sammen med Bavarian Nordic har Janssen nu udvidet udviklingen og produktionen. Ud over dem, der får vaccinen i januar, bliver 250.000 doser tilgængelige til kliniske afprøvninger før maj 2015. Virksomhederne regner også med at producere over en million doser det kommende år.

”Der er i dag et stort behov for at udvikle en vaccine mod Ebola. Resultatet fra de prækliniske studier har vist, at vaccinen kan give beskyttelse mod Ebola – derfor sætter vi alle sejl til. Det er også glædeligt, at vi på den baggrund kan medvirke til at udvikle life science-industrien i Norden”, siger Lars Johansson.

Samarbejdet mellem Janssen og Bavarian Nordic om vacciner fortsætter, og dette er første skridt mod udvikling af multivalente vacciner mod Ebola- og Marburgviruset.

Om Ebola
Ebola skyldes et virus og er ofte livstruende. Ebola er en type viral hæmoragisk feber, som også kaldes bløderfeber. Mange af de smittede med Ebola udvikler hurtigt influenzalignende symptomer med høj feber, mathed, hovedpine samt mave- og muskelsmerter. Det kan tage fra to til 21 dage efter, at man er blevet smittet. Derefter følger opkastninger, diarré, udslæt samt lever- og nyresvigt. Til sidst i sygdomsforløbet kan der opstå blødninger. Ebola smitter fra menneske til menneske, bl.a. gennem inficerede legemsvæsker som spyt og blod, men også via nys og hoste. Ebola har en dødelighed på op til 90 % ifølge Verdenssundhedsorganisationen WHO. I øjeblikket finders der ingen godkendt vaccine, behandling eller kur mod denne sygdom.

Yderligere information:
Inger Sandberg, isandber@its.jnj.com,
+45  299 982 56


Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

Janssens Ebola-vaccine har vist meget gode resultater i den prækliniske fase. Derfor bruger virksomheden nu omkring 1.200 millioner dansk kroner på at fremskynde produktionen af vaccinen. Allerede i starten af januar 2015 bliver vaccinen testet på raske frivillige. I 2015 regner Janssen med at kunne producere over en million doser.

Læs mere »
Media-no-image

ESMO Sept 28th 2014 in Madrid: Presentation of the COU-AA-302 study

Nyheder   •   2014-09-25 11:00 CEST

Charles Ryan, M.D., Professor of Clinical Medicine, Urology at the University of California, San Francisco, and lead investigator of the COU-AA-302 study, will on Sunday September 28th 11.00 – 12.30 present the following abstract at ESMO:

Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy.

Find the abstract here

For media enquiries and interviews with Charles Ryan please contact:
Satu Glawe, +49 172 294 6264, sglawe@its.jnj.com
Johan Dahlin, +46 72 553 9230, jdahlin@its.jnj.com

Charles Ryan, M.D., Professor of Clinical Medicine, Urology at the University of California, San Francisco, and lead investigator of the COU-AA-302 study, will on Sunday September 28th 11.00 – 12.30 present the following abstract at ESMO

Læs mere »
Media-no-image

September er måneden for opmærksomhed på blodkræft... Hvad har du i blodet?

Nyheder   •   2014-09-10 18:56 CEST


Janssen EMEA lancerer en ny kampagne på de sociale medier, som vi kalder "What's in your blood?" Den spændende og informative kampagne er baseret på det velkendte udtryk "It's in my blood" (Jeg har det i blodet), som bruges til at beskrive en persons karakter eller noget, som man synes er en del af en selv. Hos Janssen synes vi for eksempel, at vi har videnskab i blodet. Kampagnen opmuntrer deltagerne til at:

·  Følge Janssen på Twitter på @JanssenEMEA og dens #WhatsinYourBlood-samtale.

·  Retweete statistikker og information om blodkræft på Twitter.

·  Bruge hashtagget #WhatsinYourBlood på alle opslag på sociale medier.

Vidste du at...

·  Blodkræft er et overbegreb for kræftformer i blodet, knoglemarven og lymfesystemet, og at de fleste er livsfarlige.2

·  Der findes cirka 140 forskellige typer blodkræft, hvoraf de vigtigste er leukæmi, lymfom og myelomatose.3 Til trods for medicinske fremskridt i de senere år kan disse sygdomme stadig ikke helbredes, og der er et stort behov for at kunne tilbyde disse patienter nye behandlingsmuligheder.

Typer af blodkræft

·  Kronisk lymfatisk leukæmi (CLL) er en form for blodkræft, der udvikler sig langsomt, og som opstår i B-cellerne. Europæiske incidensrater blandt mænd og kvinder er hhv. cirka 5,87 og 4,01 tilfælde pr. 100.000 personer årligt.4

·  En sjælden og aggressiv form for lymfom er Mantle-celle-lymfom (MCL), hvis incidens i Europa estimeres til cirka 0,45 tilfælde pr. 100.000 personer årligt.5

·  Myelomatose er den næstmest almindelige form for knoglekræft og tegner sig for 1 % af alle kræfttilfælde.6

Det er vigtigt at øge forståelsen af og opmærksomheden på blodkræft, ikke kun i september måned men hver dag, i håb om at vi bedre kan hjælpe patienter, der lever med kræft. Janssen arbejder for at ændre kræft til en kronisk sygdom, der kan forhindres eller kureres, ved at tilbyde ekstraordinære diagnostiske og terapeutiske løsninger, der forlænger patienternes liv.

REFERENCER

1  Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Tilgængelig på: http://globocan.iarc.fr Senest tilgået den 16. juli 2014.

2  Anthony Nolan. What is blood cancer? Tilgængelig på: http://www.anthonynolan.org/blood-cancers-and-disorders/what-blood-cancer Senest tilgået den 16. juli 2014.

3  Leukaemia CARE. About Blood Cancer. Tilgængelig på: http://www.leukaemiacare.org.uk/about-blood-cancer Senest tilgået den 16. juli 2014.

4  Sant, M, et al. Incidence of hematological malignancies in Europe by morphological subtype: results of the HAEMACARE project. Blood. 2010; 116(19): 3724-34.

5  Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011;21:293-8.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324–

September er måneden for opmærksomhed på blodkræft. Det er en vigtig mulighed for at skabe øget opmærksomhed, uddanne og mobilisere støtte til emner omkring blodkræft, som diagnosticeres hos mere end 900.000 mænd, kvinder og børn hvert år.1

Læs mere »
Media-no-image

Johnson & Johnson and Janssen respond to Ebola crisis with commitment to accelerate vaccine program

Pressemeddelelser   •   2014-09-04 21:38 CEST

New Brunswick, NJ, September 4, 2014 – Johnson & Johnson today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.

“We recognize the urgency of the situation and the need to collaborate with multiple partners to develop treatment and preventive solutions for Ebola. I also would like to stress the importance of collaborating with Nordic partners which will strengthen the industry in the region”, says Lars Johansson, Managing Director Janssen Nordic.

Nordic media inquiries:
Andreas Palmborg, Medical Advisor, +46 701-851038, apalmbor@its.jnj.com
Lars Johansson, Managing Director Janssen Nordic, +46 (8) 6265060, ljohans1@its.jnj.com

Janssen’s Press Release, click here.


Lægemiddelvirksomheden Janssen arbejder for at opfylde vore dages store og vigtige medicinske behov. Vi arbejder med forskning og udviklingen inden for følgende alvorlige sygdomme:  prostatakræft, skizofreni, Alzheimers sygdom, hiv/aids, hepatitis C, tuberkulose, psoriasisartrit og diabetes. Vores medarbejdere er engagerede i at medvirke til at tilbyde patienter nye medicinske løsninger, produkter og ydelser. Janssen er en verdensomspændende virksomhed med medarbejdere i godt 50 lande, inklusive de nordiske lande.  

New Brunswick, NJ, September 4, 2014 – Johnson & Johnson today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.

Læs mere »

Billeder & Videoer 9 billeder

Kontaktpersoner 1 kontaktperson

  • Pressekontakt
  • Inger Sandberg, Public Affairs Leader
  • Public Affairs & Tender
  • isandber@its.jnj.com
  • +45 459 482 82